Replies to post #18061 on Synaptogenix Inc (SNPX)

[VividC]

Bryostatin Treatment (at Week #13) in the 1st trial improved Severe Impairment Battery (SIB) scores over baseline (+4.5 over baseline, p<.04, 2-tailed, pre-specified exploratory analyses of AD
patients, MMSE 14 – 4, vs. placebo, without chronic Namenda, Farlow et al., J. Alz. Dis., 2019). In a second pilot trial, Bryostatin caused significant SIB improvement (+4.12 over baseline) in the pre-specified Moderate Stratum (MMSE 10 – 14) of advanced AD patients without Namenda (p < .005, 2-tailed). In both trials, trend analyses demonstrated increased drug benefit with increasing dosing number. In a pooled trend analysis of Studies #202, 203, Bryostatin caused highly significant benefit (p<.001) and Placebo was NS.
https://www.synaptogen.com/wp-content/uploads/2021/07/ESCIOBAADP.pdf